Back to Search Start Over

Time to Treatment Initiation for Breast Cancer During the 2020 COVID-19 Pandemic.

Authors :
Hawrot K
Shulman LN
Bleiweiss IJ
Wilkie EJ
Frosch ZAK
Jankowitz RC
Laughlin AI
Source :
JCO oncology practice [JCO Oncol Pract] 2021 Sep; Vol. 17 (9), pp. 534-540. Date of Electronic Publication: 2021 Mar 12.
Publication Year :
2021

Abstract

Purpose: The COVID-19 pandemic has posed significant pressures on healthcare systems, raising concern that related care delays will result in excess cancer-related deaths. Because data regarding the impact on patients with breast cancer are urgently needed, we aimed to provide a preliminary estimate of the impact of COVID-19 on time to treatment initiation (TTI) for patients newly diagnosed with breast cancer cared for at a large academic center.<br />Methods: We conducted a retrospective study of patients with newly diagnosed early-stage breast cancer between January 1, 2020, and May 15, 2020, a time period during which care was affected by COVID-19, and an unaffected cohort diagnosed between January 1, 2018 and May 15, 2018. Outcomes included patient volume, TTI, and initial treatment modality. Adjusted TTI was compared using multivariable linear regression.<br />Results: Three hundred sixty-six patients were included. There was an 18.8% decrease in patient volume in 2020 (n = 164) versus 2018 (n = 202). There was no association between time of diagnosis (pre-COVID-19 or during COVID-19) and adjusted TTI ( P = .926). There were fewer in situ diagnoses in the 2020 cohort ( P = .040). There was increased use of preoperative systemic therapy in 2020 (43.9% overall, 20.7% chemotherapy, and 23.2% hormonal therapy) versus 2018 (16.4% overall, 12.4% chemotherapy, and 4.0% hormonal therapy) ( P < .001).<br />Conclusion: TTI was maintained among patients diagnosed and treated for breast cancer during the COVID-19 pandemic at a single large academic center. There was a decrease in patient volume, specifically in patients with in situ disease and a shift in initial therapy toward the use of preoperative hormonal therapy.<br />Competing Interests: Lawrence N. ShulmanResearch Funding: Celgene Ira J. BleiweissHonoraria: Bard BiopsySpeakers' Bureau: Bard Biopsy, Philips Digital Imaging Rachel C. JankowitzHonoraria: EisaiConsulting or Advisory Role: MerckNo other potential conflicts of interest were reported.

Details

Language :
English
ISSN :
2688-1535
Volume :
17
Issue :
9
Database :
MEDLINE
Journal :
JCO oncology practice
Publication Type :
Academic Journal
Accession number :
33710914
Full Text :
https://doi.org/10.1200/OP.20.00807